The Ewing family of tumors and the search for the Achilles' heel

Current Opinion in Oncology

Volumn 11, Issue 4, 1999, Pages 275-284

  Kovar, Heinrich ^a   Aryee, Dave ^a   Zoubek, Andreas ^a  

^a CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CD99 ANTIGEN;

CANCER GENETICS; CELL DEATH; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; EWING SARCOMA; GENE REARRANGEMENT; NEUROECTODERM TUMOR; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR DIFFERENTIATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ONCOGENE PROTEINS, FUSION; SARCOMA, EWING'S;

EID: 0033063289     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199907000-00007     Document Type: Review

References (81)

1. 1 Kovar H: Progress in the molecular biology of Ewing tumors. Sarcoma 1998, 2:3-17.
2. 2 Zucman-Rossi J, Legoix P, Victor JM, Lopez B, Thomas G: Chromosome translocation based on illegitimate recombination in human tumors. Proc Natl Acad Sci U S A 1998, 95:11786-11791. The authors provide a detailed analysis of chromosomal junctions in 77 EFT witht(11;22) rearrangements. In human solid tumors, no other translocation has been investigated in such detail. Based on the comparison of germline and rearranged sequences, the authors suggest an illegitimate recombination mechanism to be the source of EWS-Fli1 rearrangements in EFT. This is a classic example for genomics research.
3. 3 Zucman J, Melot T, Desmaze C, Ghysdael J, Plougastel B, Peter M. et al: Combinatorial generation of variable fusion proteins in the Ewing family of tumours. EMBO J 1993, 12:4481-4487.
4. 4 Kovar H, Aryee DN, Jug G, Henockl C, Schemper M, Delattre O, et al.: EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996, 7:429-437.
5. 5 Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES: Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995, 11:1049-1054.
6. 6 Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y: EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997, 99:239-247.
7. 7 Toretsky JA, Connell Y, Neckers L, Bhat NK: Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997, 31:9-16
8. 8 Wang M, Xie Y, Girnita L, Nilsson G, Dricu A, Wejde J, Larsson O: Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells. Exp Cell Res 1999, 246:38-46. The authors describe modulation of EWS-Fli1 expression and EFT cell growth by inhibitors of HMG-CoA reductase and N-linked glycosylation. Because the authors found that the chimeric transcription factor itself was not glycosylated, they suggest involvement of growth factor-dependent signalling pathways in the regulation of EWS-Fli1.
9. 9 Carlberg M, Dricu A, Blegen H, Wang M, Hjertman M. Zickert P, et al.: Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface: evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth. J Biol Chem 1996, 271:17453-17462.
10. 10 Carlberg M, Larsson O: Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts. Exp Cell Res 1996, 223:142-148.
11. 11 Toretsky JA, Kalebic T, Blakestey V, LeRoith D, Helman LJ: The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J Biol Chem 1997, 272:30822-30827,
12. 12 Scotlandi K, Benini S, Nanni P, Lollini PL, Nicoletti G, Landuzzi L, et al.: Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998, 58:4127-4131. The authors present an in vivo model for antibody therapy of EFT. They innoculated athymic mice with EFT cell lines and and treated them with IGF-R antibody. They found tumor incidence, size, and metastases to be decreased due to an increase in apoptosis, inhibition of growth, and modulation of migration of the transplanted tumor cells.
13. 13 Arvand A, Bastians H, Welford SM, Thompson AD, Ruderman JV, Denny CT: EWS/FLI1 up regulates mE2-C, a cyclin-selective ubiquitin conjugating enzyme involved in cyclin B destruction. Oncogene 1998, 17:2039-2045. A further product from the screen for differential gene expression in EWS-Fli1 transformed versus EWS-Fli1 resistant NIH3T3 celts, as developed in Chris Denny's lab. The authors describe a protein involved in rapid turnover of cyclin B, a regulatory component of cell cycle progression, to be up-regulated in NIH3T3 cells transformed by either EWS-Fli1, cMYC, or v-ABL.
14. 14 Kwiatkowski BA, Bastian LS, Bauer TRJ, Tsai S, Zielinska-Kwiatkowska AG, Hickstein DD: The ets family member Tel binds to the Fli-1 oncoprotein and inhibits its transcriptional activity. J Biol Chem 1998, 273:17525-17530.
15. 15 Carrere S, Verger A, Flourens A, Stehelin D, Duterque-Coquillaud M: Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene 1998, 16:3261-3268.
16. 16 Darby TG, Meissner JD, Ruhlmann A, Mueller WH, Scheibe RJ: Functional interference between retinoic acid or steroid hormone receptors and the oncoprotein Fli-1. Oncogene 1997, 15:3067-3082.
17. 17 Fitzsimmons D, Hodsdon W, Wheat W, Maira SM, Wasylyk B, Hagman J: Pax-5 (BSAP) recruits Ets proto-oncogene family proteins to form functional ternary complexes on a B-cell-specific promoter. Genes Dev 1996, 10:2198-2211.
18. 18 Magnaghi Jaulin L, Masutani H, Robin P, Lipinski M, Harel Bellan A: SRE elements are binding sites for the fusion protein EWS-FLI-1. Nucleic Acids Res 1996, 24:1052-1058.
19. 19 Watson DK, Robinson L, Hodge DR, Kola I, Papas TS, Seth A: FLI1 and EWS-FLI1 function as ternary complex factors and ELK1 and SAP1a function as ternary and quaternary complex factors on the Egr1 promoter serum response elements. Oncogene 1997, 14:213-221.
20. 20 Ling Y, West AG, Roberts EC, Lakey JH, Sharrocks AD: Interaction of transcription factors with serum response factor. Identification Of the elk-1 binding surface. J Biol Chem 1998, 273:10506-10514.
21. 21 Zhang D, Paley AJ, Childs G: The transcriptional repressor ZFM1 interacts with and modulates the ability of EWS to activate transcription. J Biol Chem 1998, 273:18086-18091.
22. 22 Peter M, Mugneret F, Aurias A, Thomas G, Magdelenat H, Delattre O: An EWS/ERG fusion with a truncated N-terminal domain of EWS in a Ewing's tumor. Int J Cancer 1996, 67:339-342.
23. 23 Lessnick SL, Braun BS, Denny CT, May WA: Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene, Oncogene 1995, 10:423-431.
24. 24 Pan S, Ming KY, Dunn TA, Li KK, Lee KA: The EWS/ATF1 fusion protein contains a dispersed activation domain that functions directly. Oncogene 1998, 16:1625-1631.
25. 25 Petermann R, Mossier BM, Aryee DN, Khazak V, Golemis EA, Kovar H: Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II. Oncogene 1998, 17:603-610. The authors describe a specific communication of a putative regulatory component of the basal transcriptional machinery, hsRPB7, with EWS-Fli1 but neither normal Fli1 nor germline EWS. This is the first demonstration of a structural change in overall protein conformation accompanying the underlying gene fusion, as EWS and EWS-Fli1 share the N-terminal protein interaction domain but only the chimeric transcription factor associated with hsRPB7. These results are supported by in vitro studies performed in Lazlo Tora's lab.
26. 26 Bertolotti A, Melot T, Acker J, Vigneron M, Delattre O, Tora L: EWS, but not EWS-FLI-1, is associated with both TFIID and RNA polymerase II: interactions between two members of the TET family, EWS and hTAFII68, and subunits of TFIID and RNA polymerase II complexes. Mol Cell Biol 1998, 18:1489-1497. In vitro reconstitution of the RNA polymerase II complex reveats association of EWS, but not EWS-Fli1, with the general transcription factor TFIID, as well as communication with components of the RNA polymerase II core enzyme. Loss or replacement of the C-terminal EWS domain, as is the case in EWS-rearranged tumor cells, changed the protein interaction pattern. Under these conditions, the authors observed association with hsRPB7, confirming the data obtained by Petermann et al, for EWS-Fli1 in EFT cells.
27. 27 Jensen GJ, Meredith G, Bushnell DA, Kornberg RD: Structure of wild-type yeast RNA polymerase II and location of Rpb4 and Rpb7. EMBO J 1998, 17:2353-2358.
28. 28 Khazak V, Sadhale PP, Woychik NA, Brent R, Golemis EA: Human RNA polymerase II subunit hsRPB7 functions in yeast and influences stress survival and cell morphology. Mol Biol Cell 1995, 6:759-775.
29. 29 Ceha HM, Balm AJ, de Jong D, van't Veer LJ: Multiple malignancies in a patient with bilateral retinoblastoma, J Laryngol Otol 1998, 112:189-192,
30. 30 Zoubek A, Simonitsch I, Panzer-Grumayer ER, Ghali D, Pfleiderer C, Haas OA, et al.: Ewing tumor after treatment of Ki-t+ anaplastic large cell lymphoma. Therapy-associated secondary neoplasm or unrelated coincidence? Cancer Genet Cytogenet 1995, 83:5-11.
31. 31 Aparicio J, Segura A, Montalar J, Verdeguer A, Castel V, Sanchez-Heras AB: "Secondary cancers after Ewing sarcoma and Ewing sarcoma as second malignant neoplasm". Med Pediatr Oncol 1998, 30:259-260.
32. 32 Dunst J, Ahrens S, Paulussen M, Rube C, Winkelmann W, Zoubek A, et al.: Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radial Oncol Biol Phys 1998, 42:379-384.
33. 33 Buckley JD, Pendergrass TW, Buckley CM, Pritchard DJ, Nesbit ME, Provisor AJ, Robison LL: Epidemiology of osteosarcoma and Ewing's sarcoma in childhood: a study of 305 cases by the Children's Cancer Group. Cancer 1998, 83:1440-1448.
34. 34 Hum L, Kreiger N, Finkelstein MM: The relationship between parental occupation and bone cancer risk in offspring. Int J Epidemiol 1998, 27:766-771.
35. 35 Lawlor ER, Mathers JA, Bainbridge T, Horsman DE, Kawai A, Healey JH, et al.: Peripheral primitive neuroectodermal tumors in adults: documentation by molecular analysis. J Clin Oncol 1998, 16:1150-1157.
36. 36 Katz RL, Quezado M, Senderowicz AM, Villalba L, Laskin WB, Tsokos M: An intra-abdominal small round cell neoplasm with features of primitive neuroectodermal and desmoplastic round cell tumor and a EWS/FLI-1 fusion transcript. Hum Pathol 1997, 28:502-509.
37. 37 Kawauchi S, Fukuda T, Miyamoto S, Yoshioka J, Shirahama S, Saito T, Tsukamoto N: Peripheral primitive neuroectodermal tumor of the ovary confirmed by CD99 immunostaining, karyotypic analysis, and RT-PCR for EWS/FLI-1 chimeric mRNA. Am J Surg Pathol 1998, 22:1417-1422.
38. 38 Marley EF, Liapis H, Humphrey PA, Nadler RB, Siegel CL, Zhu X, et al.: Primitive neuroectodermal tumor of the kidney-another enigma: a pathologic, immunohistochemical, and molecular diagnostic study. Am J Surg Pathol 1997, 21:354-359.
39. 39 Quezado M, Benjamin DR, Tsokos M: EWS/FLI-1 fusion transcripts in three peripheral primitive neuroectodermal tumors of the kidney. Hum Pathol 1997, 28:767-771.
40. 40 Sheaff M, McManus A, Scheimberg I, Paris A, Shipley J, Baithun S: Primitive neuroectodermal tumor of the kidney confirmed by fluorescence in situ hybridization. Am J Surg Pathol 1997, 21:461-468.
41. 41 Takeuchi T, Iwasaki H, Ohjimi Y, Ohshima K, Kaneko Y, Ishiguro M, et al.: Renal primitive neuroectodermal tumor: a morphologic, cytogenetic, and molecular analysis with the establishment of two cultured cell lines. Diagn Mol Pathol 1997, 6:309-317.
42. 42 Tsuji S, Hisaoka M, Morimitsu Y, Hashimoto H, Jimi A, Watanabe J, et al.: Peripheral primitive neuroectodermal tumour of the lung: report of two cases. Histopathology 1998, 33:369-374.
43. 43 Maurici D, Perez-Atayde A, Grier HE, Baldini N, Serra M, Fletcher JA: Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet 1998, 100:106-110.
44. 44 Armengol G, Tarkkanen M, Virolainen M, Forus A, Valle J, Bohling T, et al.: Recurrent gains of 1 q, 8 and 12 in the Ewing family of tumours by comparative genomic hybridization. Br J Cancer 1997, 75:1403-1409.
45. 45 Knuutila S, Armengol G, Bjorkqvist AM, el-Rifai W, Larramendy ML, et al.: Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet 1998, 100:25-30.
46. 46 Lawlor ER, Lim JF, Tao W, Poremba C, Chow CJ, Kalousek IV, et al.: The Ewing tumor family of peripheral primitive neuroectodermal tumors expresses human gastrin-releasing peptide. Cancer Res 1998, 58:2469-2476.
47. 47 Nagy A, Armatis P, Cai RZ, Szepeshazi K, Halmos G, Schally AV: Design, synthesis, and in vitro evaluation of cylotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci U S A 1997, 94:652-656.
48. 48 Srivastava RK, Srivastava AR, Cho-Chung YS: Synergistic effects of 8-chlorocyclic-AMP and retinoic acid on induction of apoptosis in Ewing's sarcoma CHP-100 cells. Clin Cancer Res 1998, 4:755-761.
49. 49 Fulda S, Los M, Friesen C, Debatin KM: Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998, 76:105-114
50. 50 Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M: Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into 3 soluble form by a metalloproteinase. Am J Pathol 1998, 153:1947-1956. These authors demonstrate CD95 and CD95-L expression by EFT cell lines and primary tumors. In contrast to an independent study by Kontny et al. (Cancer Res 1998, 58:5842-5849), the authors found that functional CD95-L was secreted into the extracellular milieu and effectively induced lysis in target cells. EFT cells remained resistant to a CD95 agonistic antibody.
51. 51 Kontny HU, Lehrnbecher TM, Chanock SJ, Mackall CL: Simultaneous expression of Fas and nonfunctional Fas ligand in Ewing's sarcoma. Cancer Res 1998, 58:5842-5849. These authors provide confirmation of CD95 and CD95-L expression in EFT cell lines. However, they also demonstrate that sensitivity to CD95 mediated killing varies depending on preincubation with interferon α in some cases. In contrast to the study by Mitsiades et al. (Am J Pathol 1998, 153:1947-1956), neither surface expression nor release of functional CD95-L could be demonstrated. The authors suggest that EFT cells do not suppress tumor-specific immune response via activation of CD95-dependent apoptosis of alloreactive T-cells.
52. 52 Ricotti E, Fagioli F, Garelli E, Linari C, Crescenzio N, Horenstein AL, et al.: c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood 1998, 91:2397-2405.
53. 53 Meyer D, Wolff CM, Stiegler P, Senan F, Befort N, Befort JJ, Remy P: XI-fli, the Xenopus homologue of the fli-1 gene, is expressed during embryogenesis in a restricted pattern evocative of neural crest cell distribution. Mech Dev 1993, 44:109-121.
54. 54 Melet F, Motro B, Rossi DJ, Zhang L, Bernstein A: Generation of a novel Fli-1 protein by gene targeting leads to a defect in thymus development and a delay in Friend virus-induced erythroleukemia. Mol Cell Biol 1996, 16:2708-2718.
55. 55 Mager AM, Grapin-Botton A, Ladjali K, Meyer D, Wolff CM, Stiegler P, et al.: The avian fli gene is specifically expressed during embryogenesis in a subset of neural crest cells giving rise to mesenchyme. Int J Dev Biol 1998, 42:561-572. This is an extensive study on early embryonal expression of avian Fli1. After detection of Xenopus and murine Fli1 in hematopoietic, endothelial and migratory neural crest cells, the authors demonstrate that the earliest expression of avian Fil1 occurs in a subset of neural crest cells, giving rise to mesenchyme. Based on their present and previous work, the authors speculate that EFT could arise from mesenchymal colls of both neural crest and mesoderm origin.
56. 56 Meyer D, Stiegler P, Hindelang C, Mager AM, Remy P: Whole-mount in situ hybridization reveals the expression of the XI-Fli gene in several lineages of migrating cells in Xenopus embryos. Int J Dev Biol 1995, 39:909-919.
57. 57 Reichel M, Gillert E, Nilson I, Siegler G, Greil J, Fey GH, Marschalek R: Fine structure of translocation breakpoints in leukemic blasts with chromosomal translocation t(4;11): the DNA damage-repair model of translocation. Oncogene 1998, 17:3035-3044.
58. 58 Knozovich SR, Hendson G, Mathers JA, Carpenter B, Lopez-Terrada D, Brown KL, Sorensen PH: Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma. Hum Pathol 1998, 29:289-294. These authors demonstrate a clonal relationship between EWS-Fli1 expressing undifferentiated tumor cells and therapy-induced neurally differentiated residual cells that lack the gene rearrangement in a case of EFT. The data may contribute to speculations about EFT histogenesis and the putative role of EWS-Fli1 in the suppression of differentiation.
59. 59 Maeda G, Masui F, Yokoyama R, Shimoda T, Matsuno Y, Mukai K, et al.: Ganglion cells in Ewing's sarcoma following chemotherapy: a case report. Pathol Int 1998,48:475-480.
60. 60 Shen J, Zhau HE, Hursting SD, Chung LW: Androgen regulation of the human pseudoautosomal gene MIC2, a potential marker for prostate cancer. Mol Carcinog 1998, 23:13-19.
61. 61 Dworzak MN, Fritsch G, Buchinger P, Fleischer C, Printz D, Zellner A, et al.: Flow cytometric assessment of human MIC2 expression in bone marrow, thymus, and peripheral blood. Blood 1994, 83:415-425,
62. 62 Hahn JH, Kirn MK, Choi EY, Kim SH, Sohn HW, Ham DI, et al.: CD99 (MIC2) regulates the LFA-1/ICAM-1-mediated adhesion of lymphocytes, and its gene encodes both positive and negative regulators of cellular adhesion. J Immunol 1997, 159:2250-2258.
63. 63 Bernard G, Breittmayer JP, de Matteis M, Trampont P, Hofman P, Senik A, Bernard A: Apoptosis of immature thymocytes mediated by E2/CD99. J Immunol 1997, 158:2543-2550.
64. 64 Choi EY, Park WS, Jung KC, Kim SH, Kim YY, Lee WJ, Park SH: Engagement of CD99 induces up-regulation of TCR and MHC class I and II molecules on the surface of human thymocytes, J Immunol 1998, 161:749-754.
65. MIC2 is highly expressed in EFT and because so far, nothing has been known about its role in this disease, the data from B-cells may be useful for EFT research as well.
66. 66 Chung DH, Lee JI, Kook MC, Kim JR, Kim SH, Choi EY, et al.: ILK (beta 1-integrin-linked protein kinase): a novel immunohistochemical marker for Ewing's sarcoma and primitive neuroectodermal tumour. Virchows Arch 1998, 433:113-117.
67. 67 Hannigan GE, Leung-Hagestcijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, et al.: Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996, 379:91-96.
68. 68 Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, et al.: Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998, 16:3628-3633.
69. 69 Paulussen M, Ahrens S, Craft AW, Dunst J, Frohlich B, Jabar S, et al.: Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998, 16:3044-3052.
70. 70 Atra A, Whelan JS, Calvagna V, Shankar AG, Ashley S, Shepherd V, et al.: High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone Marrow Transplant 1997, 20:843-846.
71. 71 Lucidarme N, Valteau-Couanet D, Oberlin O, Couanet D, Kalifa C, Beaujean F, et al.: Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant 1998, 22:535-540.
72. 72 Delepine N, Delepine G, Cornille H, Voisin MC, Brun B, Desbois JC: Prognostic factors in patients with localized Ewing's sarcoma: the effect on survival of actual received drug dose intensity and of histologic response to induction therapy. J Chemother 1997, 9:352-363.
73. 73 Picci P, Rougraff BT, Bacci G, Neff JR, Sangiorgi L, Cazzola A, et al.: Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J Clin Oncol 1993, 11:1763-1769.
74. 74 Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH: The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998, 80:1020-1033.
75. 75 Fagnou C, Michon J, Peter M, Bernoux A, Oberlin O, Zucker JM, et al.: Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Societe Française d'Oncologie Pediatrique. J Clin Oncol 1998, 16:1707-1711. These authors studied the incidence of RT-PCR detectable minimal residual disease in the bone marrow and blood of EFT patients at diagnosis. They could detect no correlation between positivity in blood and bone marrow. Tumor cell detection by RT-PCR for EWS-Fli1 in the bone marrow was highly associated with the presence of clinically overt metastases and, consequently, with adverse outcome in patients. However, the authors have made no distinction between localized and disseminated disease.
76. 76 Zoubek A, Ladenstein R, Windhager R, Amann G, Fischmeister G, Kager L, et al.: Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer 1998, 79:56-60. These authors performed the first RT-PCR study on minimal residual disease in the bone marrow of EFT patients that carefully considers the extent of minimal residual disease at diagnosis, as well as the clinical course of the disease. The data confirm a high association of heavy bone marrow involvement with bone or bone marrow metastasis. Half of the patients with lung metastases and one third of patients with localized disease scored positive when tested using RT-PCR. For the latter group, preliminary statistical evaluation of the data suggests a tendency toward adverse outcome correlating with bone marrow positivity when tested with RT-PCR.
77. 77 De Alava E, Lozano MD, Patino A, Sierrasesumaga L, Pardo-Mindan FJ: Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. Diagn Mol Pathol 1998, 7:152-157.
78. 78 Zoubek A, Kovar H, Kronberger M, Amann G, Windhager R, Gruber B. Gadner H: Mobilization of tumour cells during biopsy in an infant with Ewing sarcoma. Eur J Pediatr 1996, 155:373-376.
79. 79 Zoubek A, Dockhorn Dworniczak B, Delattre O, Christiansen H, Niggli F, Gatterer Menz I, et al.: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J Clin Oncol 1996, 14:1245-1251.
80. 80 De Alava E, Kawai A, Healey JH, Fligman I, Meyers P, Huvos AG, et al.: EWS-FLI1 fusion transcript stucture is an independent determinant of prognosis in Ewings sarcoma. J Clin Oncol 1998, 16:1248-1255. Confirmation of the prognostic significance of EWS-Fli1 fusion type in EFT patients with localized disease as suggested previously by Zoubek et al. (J Clin Oncol 1996, 74:1245-1251.)
81. 81 Ginsberg JP, De Alava E, Ladanyi M, Wexler LH, Kovar H, Paulussen M, et al.: EWS-FLi1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 1999, in press.